Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Aboagye, Eric O.; Gilbert, Fiona J.; Fleming, Ian N.; Beer, Ambros J.; Cunningham, Vincent J.; Marsden, Paul; Visvikis, Dimitris; Gee, Antony D.; Groves, Ashley M.; Kenny, Laura; Cook, Gary; Kinahan, Paul E.; Myers, M. J.; Clarke, Lawrence

doi:10.1007/s00330-011-2311-3

Cited by 15 publications

(11 citation statements)

References 78 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above studies complement haemodynamic measurements of tumour perfusion detected by 15 O-H 2 O dynamic PET imaging, considered the gold standard for imaging tumour blood flow in patients [138]. 15 O-H 2 O has been applied successfully in clinical studies to evaluate antiangiogenic therapy [139].…”

Section: Imaging Tumour Angiogenesismentioning

confidence: 98%

Radiopharmaceuticals as probes to characterize tumour tissue

Alam

Arshad

Nguyen

et al. 2015

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Tumour cells exhibit several properties that allow them to grow and divide. A number of these properties are detectable by nuclear imaging methods. We discuss crucial tumour properties that can be described by current radioprobe technologies, further discuss areas of emerging radioprobe development, and finally articulate need areas that our field should aspire to develop. The review focuses largely on positron emission tomography and draws upon the seminal 'Hallmarks of Cancer' review article by Hanahan and Weinberg in 2011 placing into context the present and future roles of radiotracer imaging in characterizing tumours.

show abstract

Section: Imaging Tumour Angiogenesismentioning

confidence: 98%

Radiopharmaceuticals as probes to characterize tumour tissue

Alam

Arshad

Nguyen

et al. 2015

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…122e125 One of the invasive methods for studying hypoxia uses O 2 electrodes in easily accessible tumours such as head and neck, cervical, and breast tumours. 51,125 Of the non-invasive imaging methods to image hypoxia, radionuclide studies using PET tracers are the most extensively studied. 124e126 Parametric PET hypoxia imaging of tissue using inhalation of 15 O 2 by measuring regional oxygen extraction fraction, and metabolic rate is shown to be more accurate than the invasive methods.…”

Section: Mfi Of Hypoxiamentioning

confidence: 99%

“…51,105,106 11 C-carbonmonoxide-PET measures blood volume (BV) up to approximately 0.1e0.2 ml blood/ml tissue in renal cancer, which is characterised by a highly vascular phenotype. 51,105,106 Other important imaging methods with established clinical use include structural imaging of vascularity using CT/ MRI angiography and functional imaging using perfusion-CT (pCT) and dynamic contrast-enhanced MRI (DCE-MRI). 107e109 pCT (Fig 8) and DCE-MRI (Fig 2) track the pharmacokinetics of injected contrast agents through the tumour vasculature, and provide a measure of vascular permeability, regional blood flow, and vascular volume.…”

Section: Figurementioning

confidence: 99%

Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?

et al. 2015

View full text Add to dashboard Cite

“…This issue embraces four seminal articles [1][2][3][4] reviewing how functional information can be accurately, repeatedly and noninvasively collected from cross-sectional imaging techniquesusing ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). This information can be used to assess factors related to the vascularity of a tumour and provide prognostic information and also the likely response to various therapeutic agents.…”

mentioning

confidence: 99%

“…The final paper is by Aboagye et al [4]: "Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials". The paper concludes that 15 O-water measurements represent the "gold standard" for assessing blood flow/tissue.…”

mentioning

confidence: 99%

Standardising measurement of tumour vascularity by imaging: recommendations for ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography

Dixon

Gilbert

2012

Eur Radiol

Self Cite

View full text Add to dashboard Cite

This review analyses the need for, and likely impact of, four subsequent papers which discuss the importance of standardisation of ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) when assessing tumour vascularity. This is particularly important when measuring the vascular effects of therapeutic agents in oncological research and practice. As imaging inexorably moves from the subjective interpretative art-form of the past into its modern role as a fully fledged objective scientific discipline, it is incumbent on all radiologists to understand the need for strict adherence to perceived best practice when evaluating lesions as part of trials. Indeed trials may only be funded by pharmaceutical companies and other grant-giving bodies if rigorous adherence to imaging protocols and quality assurance is in place. Key Points • Various imaging methods can now robustly assess tumour vascular support.• US, CT, MRI and PET are increasingly used to assess tumour vascularity.• These techniques have reached technical maturity for use in therapeutic oncological trials.• Consensus guidelines about using these techniques in assessing tumour vascularity are introduced.• Image acquisition protocols and quality assurance must be established for large trials.Keywords Tumour vascularity . Angiogenesis . Early phase trials . Perfusion quantification . Response assessmentThis issue embraces four seminal articles [1-4] reviewing how functional information can be accurately, repeatedly and noninvasively collected from cross-sectional imaging techniquesusing ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). This information can be used to assess factors related to the vascularity of a tumour and provide prognostic information and also the likely response to various therapeutic agents. Such prediction of response is of crucial importance when the therapeutic agent is costly and carries serious side effects, such as many oncological drugs. As change in vascularity may be a genuine indication of response to treatment, together with associated alterations in glucose metabolism, these new radiological techniques become of paramount importance. Indeed, the tumour micro-environment is now an accepted biomedical marker [5] and it is important that radiological techniques are used to the full in order to assess such aspects. Thus, oncologists, health administrators and pharmaceutical companies now view such functional studies as an extremely important tool in their search for the optimal and most cost-effective therapy that can improve the health of the patient with the minimum of side effects. In this era of stratified medicine the importance of phenotyping the patient becomes increasingly relevant in order to select the correct combination of therapies. Another reason for the need for these papers is that pharmacological companies demand robust, repeatable, reproducible and reliable measures, which are readi...

show abstract

Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Cited by 15 publications

References 78 publications

Radiopharmaceuticals as probes to characterize tumour tissue

Radiopharmaceuticals as probes to characterize tumour tissue

Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?

Standardising measurement of tumour vascularity by imaging: recommendations for ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography

Contact Info

Product

Resources

About